- Home
- SGMT vs NBTX Comparison
SGMT vs NBTX Comparison
Compare SGMT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- NBTX
- Stock Information
- Founded
- SGMT 2006
- NBTX 2003
- Country
- SGMT United States
- NBTX France
- Employees
- SGMT N/A
- NBTX N/A
- Industry
- SGMT
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- SGMT
- NBTX Health Care
- Exchange
- SGMT Nasdaq
- NBTX Nasdaq
- Market Cap
- SGMT 230.3M
- NBTX 211.9M
- IPO Year
- SGMT 2023
- NBTX 2020
- Fundamental
- Price
- SGMT $6.15
- NBTX $10.20
- Analyst Decision
- SGMT Strong Buy
- NBTX Strong Buy
- Analyst Count
- SGMT 7
- NBTX 1
- Target Price
- SGMT $26.57
- NBTX $8.00
- AVG Volume (30 Days)
- SGMT 461.6K
- NBTX 14.0K
- Earning Date
- SGMT 11-12-2025
- NBTX 09-18-2025
- Dividend Yield
- SGMT N/A
- NBTX N/A
- EPS Growth
- SGMT N/A
- NBTX N/A
- EPS
- SGMT N/A
- NBTX N/A
- Revenue
- SGMT N/A
- NBTX N/A
- Revenue This Year
- SGMT N/A
- NBTX N/A
- Revenue Next Year
- SGMT N/A
- NBTX $74.67
- P/E Ratio
- SGMT N/A
- NBTX N/A
- Revenue Growth
- SGMT N/A
- NBTX N/A
- 52 Week Low
- SGMT $1.73
- NBTX $2.76
- 52 Week High
- SGMT $11.41
- NBTX $10.96
- Technical
- Relative Strength Index (RSI)
- SGMT 30.58
- NBTX 65.13
- Support Level
- SGMT $6.77
- NBTX $9.32
- Resistance Level
- SGMT $7.35
- NBTX $10.46
- Average True Range (ATR)
- SGMT 0.41
- NBTX 0.59
- MACD
- SGMT -0.07
- NBTX 0.01
- Stochastic Oscillator
- SGMT 5.57
- NBTX 74.15
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.